A Phase 3 interventional study of Vatiquinone in Inherited Mitochondrial Disease, sponsored by PTC Therapeutics. Completed at 26 sites in 7 countries. Per ClinicalTrials.gov, last updated 2025-12-22.
Sponsored by PTC Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Leigh Disease with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Leigh Disease · United States.
Among the 14 studies in Leigh Disease with a site in United States, this one is one of 2 that started in 2022, is the only one in phase 3, and was the 12th registered.
20 studies on the registry are indexed under Leigh Disease; 9 are open to participants now.
Browse Leigh Disease studies →6 of the 14 studies in Leigh Disease with a site in United States are open now. Recruiting first, the newest first:
The University of Texas Health Science Center, Houston · Sites in United States
Ages 0 days–100 yrs
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 4 wk–115 yrs · Healthy volunteers
Columbia University · Sites in United States, Canada
Healthy volunteers
Sanford Health · Sites in United States
Matthew Demczko · Sites in United States
Ages 6 mo–55 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Leigh Disease studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 2
First in 2010; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 101 is above the median of 31 across 10 interventional studies indexed under Leigh Disease.
Median enrollment 35 across the 7 interventional studies, 750 across the 6 observational. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 8 most frequent:
PTC Therapeutics is the lead sponsor of 65 studies on the registry; 3 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 14 (78%) have results posted.
PTC Therapeutics has 5 studies filed under Leigh Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Leigh Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01803906Columbia UniversityTissue Sample Study for Mitochondrial Disorders | 2026-12 |
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Leigh Disease with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical study or treatment plan.
The study will continue until vatiquinone becomes commercially available or the program is terminated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive vatiquinone oral solution (100 milligrams \[mg\]/milliliter \[mL\]), up to 400 mg, administered orally or via feeding tube 3 times daily (TID).
Drug: Vatiquinone
Vatiquinone will be administered per dose and schedule specified in the arm description.
Also known as: PTC743
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs included both serious adverse events (SAEs) and non-serious AEs. A TEAE was defined as an AE that had an onset date or date of worsening on or after the first dose of study drug and within 30 days of the date of the last dose of treatment. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.
Time frame: Baseline (Day 1) up to 30 days after last dose of study drug (956 days)
| Milestone | Vatiquinone |
|---|---|
| Started | 101 |
| Received at least 1 dose of study drug | 101 |
| Completed | 0 |
| Not completed | 101 |
| Withdrew: Adverse event | 6 |
| Withdrew: Sponsor's decision | 85 |
| Withdrew: Death | 1 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Other than specified | 3 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs included both serious adverse events (SAEs) and non-serious AEs. A TEAE was defined as an AE that had an onset date or date of worsening on or after the first dose of study drug and within 30 days of the date of the last dose of treatment. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.
| Participants | Vatiquinone |
|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 91 |
Collected over Baseline (Day 1) up to 30 days after last dose of study drug (956 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vatiquinone | 7/101 (6.9%) | 45/101 (44.6%) | 59/101 (58.4%) |
| Event | Vatiquinone |
|---|---|
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 11/101 |
| PneumoniaInfections and infestations | 10/101 |
| VomitingGastrointestinal disorders | 4/101 |
| COVID-19Infections and infestations | 3/101 |
| Urinary tract infectionInfections and infestations | 3/101 |
| Status epilepticusNervous system disorders | 3/101 |
| Generalised oedemaGeneral disorders | 2/101 |
| BronchitisInfections and infestations | 2/101 |
| InfluenzaInfections and infestations | 2/101 |
| Lower respiratory tract infectionInfections and infestations | 2/101 |
| Event | Vatiquinone |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 14/101 |
| COVID-19Infections and infestations | 13/101 |
| PyrexiaGeneral disorders | 12/101 |
| VomitingGastrointestinal disorders | 11/101 |
| Urinary tract infectionInfections and infestations | 9/101 |
| SeizureNervous system disorders | 9/101 |
| NasopharyngitisInfections and infestations | 7/101 |
| DiarrhoeaGastrointestinal disorders | 6/101 |
| PneumoniaInfections and infestations | 6/101 |
| Respiratory tract infectionInfections and infestations | 6/101 |
Safety population included all participants who received at least 1 dose of vatiquinone in the study.
| Age, Continuous(years) | Vatiquinone |
|---|---|
| Mean | 15.5 ± 11.56 |
| Sex: Female, Male(Participants) | Vatiquinone |
|---|---|
| Female | 49 |
| Male | 52 |
| Race/Ethnicity, Customized(Participants) | Vatiquinone |
|---|---|
| Race — American Indian/Alaska Native | 1 |
| Race — Asian | 8 |
| Race — Black/African American | 2 |
| Race — White | 83 |
| Race — Other | 1 |
| Race — Unknown | 1 |
| Race — Missing | 5 |
| Race/Ethnicity, Customized(Participants) | Vatiquinone |
|---|---|
| Ethnicity — Hispanic or Latino | 9 |
| Ethnicity — Not Hispanic or Latino | 86 |
| Ethnicity — Not Reported | 3 |
| Ethnicity — Unknown | 2 |
| Ethnicity — Missing | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2022 to primary completion in Apr 2025, 33 months.
Results were first posted in Dec 2025, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha-tocotrienol quinone